significance in the younger cohort (57% for cases GNNKÀ vs 19% for cases GNNKÀ plus GNNK þ , P ¼ 0.04). The statistical significance was lost when PFS was considered, notwithstanding a persistent trend to significance (58% for cases with GNNKÀ vs 25% for cases showing both GNNKÀ plus GNNK þ , P ¼ 0.12). However, the absence of GNNK þ did highly condition both OS and PFS in the high cytogenetic risk subgroup (3-year OS 100% for cases GNNKÀ vs 6% for those carrying both isoforms, P ¼ 0.01; PFS 66 vs 8%, P ¼ 0.05).
On the other hand, sorafenib (BAY 43-9006, Nexavar, Bayer, Germany) is a multikinase inhibitor with activity against Raf kinase and several receptor tyrosine kinases, including vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor, FLT3, Ret and c-Kit, the D816V mutants excluded. Pronounced apoptosis was recently observed in blasts from patients with acute myeloid leukaemia. 8 On the basis of the above reported data, it would be useful to screen all AML patients for GNNKÀ and GNNK þ expression, in order to design ab initio a more aggressive therapeutic strategy, perhaps including transplantation options, for cases carrying both GNNKÀ and GNNK þ c-Kit isoforms. Results of a multicenter phase II trial for older patients with c-Kitpositive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. In myelodysplastic syndromes (MDS) chromosomal aberrations have many clinical implications 1,2 but a significant proportion of patients do not exhibit cytogenetic abnormalities, while in some patients, cytogenetic analysis may not provide an informative result. Recently, we investigated various possibilities to improve cytogenetic diagnosis of MDS. Currently, in MDS using routine metaphase cytogenetics (MC) defects are found only in 40-60% of patients, 3 and MC analysis often yields uninformative results. We will share some of the important preliminary results here.
While exploring high-density single nucleotide polymorphism DNA arrays (SNP-A) as genotyping tool, we realized that this technique can also be applied for detection of copy number (CN) changes, CN neutral loss of heterozygosity (LOH), also known as uniparental disomy (UPD), and allow for increased levels of genomic resolution. The resulting DNA-based SNP 'karyograms' facilitate detection of chromosome defects without the need for dividing cells as in conventional cytogenetics. We hypothesized that chromosomal changes may be present in most MDS patients, and that such a cytogenetic technique with a higher resolution will result in detection of karyotypic defects in a higher proportion of patients.
We have tested 66 patients with MDS (age range 26-86) and 29 healthy individuals (age range 27-61) used as controls ( Table 1 ). The Affymetrix Gene Chip Mapping 50K Assay Kit (Affymetrix, Santa Clara, CA, USA) was used. We confirmed newly detected lesions using microsatellite (MS) analysis and determination of gene CN using a Real-Time TaqMan chemistry protocol. By analysis of heterozygous SNP calls within the X chromosome we estimated the accuracy of the array to be 499%. Expected differences in the signal intensity of regions affected by CN polymorphisms in controls were detected, and consequently, if found in MDS patients were not deemed significant.
In general, 50K SNP-A confirmed the lesions identified by MC but also detected new, previously cryptic defects, including UPD (Table 2 and Figure 1 ). For example, SNP array analysis confirmed the presence of 2p and 5q deletion as seen in a patient with a 46,XY,del(2)(p11.2p15),del(5)(q13q33) karyotype ( Figure 1a ) and the presence of an extra copy of chromosome 13 in a patient with trisomy 13 (Figure 1b) .
When LOH was investigated by SNP-array, more subtle DNA variants could be identified, including microduplications and microdeletions (examples shown in Table 2 ). An unexpected finding was the identification of cytogenetically cryptic aberrations, including CN-neutral LOH (for example, 6p, Figure 1c ). This type of LOH found by SNP-A was present despite having two copies of each respective chromosome. Importantly, this segmental LOH remains undetectable by traditional cytogenetic banding techniques, as it does not alter the chromosome banding pattern. SNP-A assessment of DNA CN was confirmed with TaqMan PCR-based quantitation using DNA from both marrow and lymphocytes (data not shown).
The distinction between LOH resulting from deletions and that due to acquired UPD is apparent when comparing the SNP analysis for patients with deletions and UPD. The segmental LOH in UPD occurs in the presence of a diploid chromosome CN shown both by SNP array and MC (see, for example, UPD6p in Figure 1c ) whereas, the 'traditional' LOH occurring in deletions is associated with loss of DNA CN in marrow cells.
Identification of a high frequency of segmental LOH due to UPD is a new finding that has significant implications for the pathogenesis of MDS and it extends the previous observations of a high frequency of LOH in chromosome 1 using MS scanning. 4 This mechanism of LOH has been described in many solid tumors, but has been rarely observed in myeloid malignancies. 5 Importantly, LOH can also occur as a result of mitotic recombination during which segments of homologous chromosomes are exchanged, leading to UPD, 6 a feature which is not recognizable in MC because the chromosome banding pattern remains preserved. While UPD is known as a mechanism leading to LOH affecting whole chromosomes in congenital abnormalities such as Prader-Willi and Angelman syndromes, formal proof for acquired segmental LOH in cancer has been described only in a limited number of reports. 7, 8 Deletions of chromosomal material could represent 'unrepaired' lesions while defects 'repaired' by mitotic recombination using the homologous chromosome would generate UPD and those lesions corrected using a nonhomologous chromosome could lead to translocations. We have shown that the presence of acquired segmental UPD in MDS is due to a somatic event; these results were independently confirmed by MS genotyping and PCR quantitation of locus CN.
Fewer patients had normal karyotypes by SNP-A as compared to MC (12 vs 39%; Po0.001). In 69% of patients with normal MC, new chromosomal lesions were identified. In 80% of patients in whom MC was unsuccessful, SNP array analysis identified abnormalities. Moreover, additional lesions were found in 83% of patients with previously known defects ( Table 1) . Using morphologic diagnosis as the gold standard, the resulting sensitivity for detection of chromosomal changes in MDS by SNP-A was 83 vs 53% for cytogenetics. Moreover, SNP-A showed a higher proportion of patients with multiple chromosomal defects for SNP arrays and MC, respectively. Based on the hypothetical assumption that chromosomal aberrations detected by SNP-A carry a similar prognostic value to those detected by MC, array-based methods could result in a higher proportion of complex karyotypes (44 vs 6%; Po0.001) and consequently a higher IPSS score. Surprisingly, we found segmental LOH due to acquired UPD in 33% MDS patients by SNP array analysis. LOH was distributed across all WHO subtypes and was present both as a solitary lesion (9%), as well in association with additional defects (24%). Acquired UPD was present in regions frequently Table 1 Results of routine metaphase cytogenetics as compared to SNP-A based karyotyping WHO subtypes (no. of patients) Metaphase karyotyping SNP karyotyping
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; NI, not informative; NG, no growth; SNP-A, single nucleotide polymorphism DNA arrays.
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affected by deletions as demonstrated by traditional cytogenetics, including 7q and 11q. Particularly informative were newly detected lesions that occurred in an overlapping fashion in multiple patients. As expected, certain chromosomes were more often affected, including loss of chromosomal material within chromosomes 1, 5, 7 and 11, or gain of chromosome 8.
Other interesting defects not previously described in the context of MDS included changes on chromosome 1p31.1 (N ¼ 6), add(2)(q37) (N ¼ 6) and del(14)(q11) (N ¼ 5). The results presented in this letter show that SNP-A analysis in MDS will allow for detection of known and previously cryptic lesions. The resulting increased detection rate is due to the improved resolution of the genomic scan, while its sensitivity remains comparable to that of MC. As a result, the proportion of patients with normal karyotype decreased compared to routine MC, and more patients showed multiple lesions. It is likely that the presence of additional changes as detected by SNP-A analysis is responsible for the variability of the clinical phenotype associated with a known karyotype. Of significant interest is that regions of UPD detected by SNP-A were also located in portions of chromosomes frequently affected by genomic losses. We suggest that SNP-A constitutes a major advance in comparison to MS-based identification of LOH. Theoretically, the resolution of SNP-A is limited only by the number of SNP probes used, while its sensitivity depends on the contribution of the dysplastic clone to the overall cellular content of the sample. One major advantage of SNP-A is the ability to perform analyses on interphase cells without the need for cell division. This advantage is reflected by the low proportion of non-informative results. Unlike traditional MC, SNP-A do not allow for the distinction of multiple clones and minor clones may remain undetected due the 'dilution' effect. In general, SNP-A showed very good correlation with MC. However, in a proportion of patients lesions detected by MC were not found by SNP-A. This discrepancy is due to various reasons, including the fact that loss of Y is not tested on the array and balanced translocations and inversions cannot be detected by this technique. Finally, the remaining discrepancy is due to lower sensitivity of SNP-A for smaller clones.
Our analysis was performed using total bone marrow. Sorted myeloid cells were not available but it is likely that lymphocyte depletion would result in a higher detection rate. Despite this shortcoming, clonal lesions were detected and the fact that the defects were seen despite the contamination suggests that the clones detected were of significant size. While this clearly decreases the sensitivity, it may be an advantage as only large likely clinically significant clones were studied.
In sum, we have written this letter as we believe that SNP-Abased karyotyping is a technology that should be further explored as it may complement metaphase karyotyping in improved prediction of clinical phenotype and prognosis in the diagnosis of MDS and allow for better mapping of the breakpoints. To our knowledge, our letter describes the first systematic application of this technology in MDS. We hope that we can inspire further investigations and discussion on innovative ways to improve cytogenetic diagnosis of MDS. Human cells are frequently exposed to DNA double-strand breaks (DSB) that are generated either by endogenous (for example, V(D)J recombination and reactive oxygen species) or by exogenous (for example, ionizing radiation and chemotherapy regimens) agents. To repair DSB and maintain genome integrity, human cells have evolved two major repair pathways: non-homologous end-joining (NHEJ) and homologous recombination (HR). HR uses homologous DNA strand as a template to repair DSB and is an error-free process.
LP
1 NHEJ repairs DSB by directly re-ligating DNA ends, which may be error-prone and may produce mis-ligation between the two chromosome ends. [2] [3] [4] In this regard, it has been shown that NHEJ repair is involved in the generation of certain chromosomal translocations in acute myeloid and lymphoid leukemia. 2, 3, 5 These chromosome translocations are thought to be correlated with highly activated NHEJ activity. 2, 3 However, the expressions of NHEJ genes in these tumors are poorly understood so far. In this study, we report a survey of NHEJ mRNA expressions in pediatric acute lymphoblastic leukemia (ALL).
To investigate a panel of NHEJ gene expressions in pediatric ALL, we examined mRNA transcripts of all NHEJ family members, including Ku70, Ku80, DNA-PK, Artemis, XRCC4,
